We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
32 result(s) found, displaying 11 to 20
-
Australian public assessment report (AusPar)AusPAR for Ultomiris (ravulizumab) for the treatment of paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome
-
Prescription medicine registrationActive ingredients: ravulizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KOSELUGO selumetinib 10 mg capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KOSELUGO selumetinib 25 mg capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ULTOMIRIS ravulizumab rch 1100 mg in 11 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial.
-
Prescription medicine registrationActive ingredients: ravulizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ULTOMIRIS ravulizumab rch 10 mg/mL concentrated solution for intravenous infusion vial.
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Eculizumab
-
Prescription medicine registrationActive ingredients: eculizumab.